French Trial Tragedy: Janssen Halts FAAH Inhibitor Trial
This article was originally published in Scrip
Executive Summary
Janssen has voluntarily suspended dosing in two Phase II studies of its experimental FAAH inhibitor JNJ-42165279; the drug is in the same class as the compound at the heart of the clinical trial tragedy in France.